[go: up one dir, main page]

AR104805A1 - METHODS AND COMPOSITIONS TO EVALUATE CANCER RESPONSE RESPONSE TO BET INHIBITORS - Google Patents

METHODS AND COMPOSITIONS TO EVALUATE CANCER RESPONSE RESPONSE TO BET INHIBITORS

Info

Publication number
AR104805A1
AR104805A1 ARP160101552A ARP160101552A AR104805A1 AR 104805 A1 AR104805 A1 AR 104805A1 AR P160101552 A ARP160101552 A AR P160101552A AR P160101552 A ARP160101552 A AR P160101552A AR 104805 A1 AR104805 A1 AR 104805A1
Authority
AR
Argentina
Prior art keywords
methods
cancer
response
subject
bet
Prior art date
Application number
ARP160101552A
Other languages
Spanish (es)
Inventor
Mesh Kathryn
L Mcleland Mark
Firestein Ron
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR104805A1 publication Critical patent/AR104805A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen métodos de tratamiento de un sujeto que tiene cáncer con un inhibidor de BET, métodos de selección de un sujeto para el tratamiento con un inhibidor de BET, métodos de predicción de la capacidad de respuesta de un sujeto que tiene cáncer a un inhibidor de BET, métodos de comunicación de la probabilidad de respuesta de un sujeto que tiene cáncer a un inhibidor de BET y métodos de modulación del tratamiento de un sujeto que se somete a un tratamiento con inhibidores de BET para cáncer. Los métodos descritos incluyen las etapas para llevar a cabo un ensayo de detección a base de ácido nucleico para detectar el nivel de expresión de un eARN transcrito de un elemento potenciador asociado con mic en una muestra que contiene células cancerosas del sujeto y determinar el nivel de expresión del eARN en las células en la muestra.Methods of treating a subject who has cancer with a BET inhibitor, methods of selecting a subject for treatment with a BET inhibitor, methods of predicting the responsiveness of a subject having cancer to an inhibitor of cancer are described. BET, methods of communicating the likelihood of response of a subject who has cancer to a BET inhibitor and methods of modulating the treatment of a subject undergoing treatment with BET inhibitors for cancer. The methods described include the steps to carry out a nucleic acid based detection assay to detect the level of expression of a transcribed eRNA of an enhancer element associated with mic in a sample containing the subject's cancer cells and determine the level of eRNA expression in the cells in the sample.

ARP160101552A 2015-05-29 2016-05-27 METHODS AND COMPOSITIONS TO EVALUATE CANCER RESPONSE RESPONSE TO BET INHIBITORS AR104805A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562168691P 2015-05-29 2015-05-29

Publications (1)

Publication Number Publication Date
AR104805A1 true AR104805A1 (en) 2017-08-16

Family

ID=56117996

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101552A AR104805A1 (en) 2015-05-29 2016-05-27 METHODS AND COMPOSITIONS TO EVALUATE CANCER RESPONSE RESPONSE TO BET INHIBITORS

Country Status (2)

Country Link
AR (1) AR104805A1 (en)
WO (1) WO2016196065A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11708600B2 (en) * 2017-10-05 2023-07-25 Decode Health, Inc. Long non-coding RNA gene expression signatures in disease diagnosis
WO2019113260A1 (en) * 2017-12-05 2019-06-13 The Regents Of The University Of Colorado A Body Corporate Genomic targets of histone deacetylase inhibitors (hdaci) and methods of use thereof
US20220305027A1 (en) * 2019-05-03 2022-09-29 Icahn School Of Medicine At Mount Sinai Methods of controlling and improving brain health
WO2021180055A1 (en) * 2020-03-09 2021-09-16 石药集团中奇制药技术（石家庄）有限公司 Use of brd4 inhibitor

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
CA2265645C (en) 1996-09-13 2007-01-23 Yoshitomi Pharmaceutical Industries Ltd. Thienotriazolodiazepine compounds and pharmaceutical use thereof
EP1276702A2 (en) 2000-03-31 2003-01-22 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
WO2006129623A1 (en) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compound and a medicinal use thereof
ES2454966T3 (en) 2007-02-01 2014-04-14 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
JP5478262B2 (en) 2007-12-28 2014-04-23 田辺三菱製薬株式会社 Anticancer drug
SI2346837T1 (en) 2008-06-26 2015-05-29 Resverlogix Corporation Methods of preparing quinazolinone derivatives
ES2821018T3 (en) 2009-04-22 2021-04-23 Resverlogix Corp New anti-inflammatory agents
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2011054845A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2011143669A2 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc Compositions and methods for treating neoplasia, inflammatory disease and other disorders
MX354217B (en) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Compositions and methods for treating leukemia.
JP5913292B2 (en) 2010-05-14 2016-04-27 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Compositions and methods for modulating metabolism
JP5844358B2 (en) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー Bromodomain inhibitors containing benzotriazolodiazepine compounds
AR084070A1 (en) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc BROMODOMINIUM INHIBITORS AND USES OF THE SAME
EP2677865A4 (en) 2011-02-23 2015-04-22 Icahn School Med Mount Sinai Inhibitors of bromodomains as modulators of gene expression
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033270A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
WO2013033420A1 (en) * 2011-08-30 2013-03-07 Whitehead Institute For Biomedical Research Methods of downregulating translocated oncogene expression using bromodomain inhibitors
DE102011082013A1 (en) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-thieno [3,2-f] [1,2,4] triazolo [4,3-a] [1,4] diazepines
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP2861255B1 (en) * 2012-06-19 2019-10-09 The Broad Institute, Inc. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy

Also Published As

Publication number Publication date
WO2016196065A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
MX2017003790A (en) DETECTION OF DIANA SEQUENCES FOR PERCEPTION OF NANOPOROS OF SYNTHETIC PROBES.
EP4368992A3 (en) Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue
EA201991105A1 (en) RISK ASSESSMENT METHODS USING TOTAL AND SPECIFIC NON-CELLULAR DNA
BR112018069849A2 (en) kit, device and method for the detection of early pancreatic cancer or pancreatic cancer precursor lesion
BR112017007965A2 (en) computer-implemented method for inferring the activity of a tgf-b cell signaling pathway in an individual; apparatus for inferring the activity of a tgf-b cellular signaling pathway in an individual; non-transient storage medium; computer program; kits for measuring expression levels of three or more tgf-b cell signaling pathway target genes in a sample from an individual; infer the activity of a tgf-b cell signaling pathway in an individual; infer the activity of a tgf-b cell signaling pathway in an individual; and use of the kit
EA201891304A1 (en) MAT2A INHIBITORS FOR THE TREATMENT OF MTAP-null MALIGNANT TUMORS
EA201692157A1 (en) SYNTHESIS OF TWO-CELLULAR NUCLEIC ACIDS
EA201790769A1 (en) DETERMINATION OF THE LEVELS OF GLYCOSAMINOGLICANES BY THE MASS SPECTROMETRY METHOD
MX2019010844A (en) Maternal plasma transcriptome analysis by massively parallel rna sequencing.
JOP20190280A1 (en) FGFR2 inhibitors for treating cholangiocarcinoma
MX2017005888A (en) Devices, systems, and methods for the detection of analytes.
AR104805A1 (en) METHODS AND COMPOSITIONS TO EVALUATE CANCER RESPONSE RESPONSE TO BET INHIBITORS
EP3837362A4 (en) IN VITRO DETECTION OF NUCLEIC ACID
CL2017001487A1 (en) Use of fgfr bread inhibitors and method for identification of cancer patients eligible for treatment with an fgfr bread inhibitor.
EA201792641A1 (en) IGFBP3 / TMEM219 AXIS INHIBITOR AND DIABETES
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms
MX2024003382A (en) Compositions and methods for detecting circulating tumor dna.
EP3758589A4 (en) TECHNIQUES FOR PREDICTING THE RECURRENCE OF CANCER CELLS USING IMPEDANCE DETECTION
CL2017001929A1 (en) Method and product
PH12015501778A1 (en) Markers associated with wnt inhibitors
EA201891478A1 (en) METHODS AND COMPOSITIONS FOR RISK ASSESSMENT FOR CANCER
BR112017023473A2 (en) nucleic acid detection and quantification method and compositions
EP3498275C0 (en) USE OF KNOWN COMPOUNDS AS D-AMINO ACID OXIDASE INHIBITORS
CL2020002715A1 (en) Compositions and methods for treating endometriosis
BR112016004450A2 (en) methods for treating a disease, for increasing the effectiveness of a treatment, for postponing and / or preventing the development of recurrence and / or resistance of a disease, for increasing sensitivity to an inhibitor, for extending the sensitivity period for an inhibitor and for extend response time to an inhibitor

Legal Events

Date Code Title Description
FB Suspension of granting procedure